Oxycodone
oxy, oxycontin, percocet, oxynorm
Opioid, Habit-forming, Depressant, Common
A semisynthetic opioid analgesic developed in 1917, prescribed primarily for pain management. It has become extremely popular as a recreational drug in some areas and carries a high potential for substance use disorder. Anectodal reports indicate the drug being a more 'stimulating' than other opioids.
Oral 60-87% | Insufflated 55-70%
3-5 days for minimal use, 5-8 for regular use.
2-4 hours
Pale violet
Avoid grapefruit juice, depressants, and diphenhydramine (DPH). These products may react negatively and can cause an overdose. Additionally, it is strongly recommended against consuming greater than 4g APAP (acetaminophen) in a day.
Note: Dosages reflect that while nasal bioavailability (BA) may be less than oral BA, nasal administration can cause an additional 'rush' (due to quicker onset); this may lead to a subjective experience of greater strength than an equivalent oral dose.
Chart shows bounded mass ranges in mg. See the table for all doses.
Light
Common
Strong
Insufflated
2.5-7.5mg
7.5-15mg
15-25mg
Oral
2.5-10mg
10-25mg
25-40mg
Onset
Duration
Insufflated
2m to 5m
3 to 5
Intravenous
0 to 1m
3 to 5
Oral_ER
0 to 40m
6 to 8
Oral_IR
0 to 20m
4 to 6
Oral
Pain relief, Respiratory depression, Sedation, Constipation, Cough suppression, Decreased libido, Difficulty urinating, Itchiness, Nausea, Pupil constriction, Stomach cramps, Appetite suppression, Euphoria, Anxiety suppression, Dream potentiation
Controlled-release oxycodone-induced seizures. - http://www.ncbi.nlm.nih.gov/pubmed/16368452Grapefruit juice enhances the exposure to oral oxycodone. - http://www.ncbi.nlm.nih.gov/pubmed/20406214Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain. - http://www.ncbi.nlm.nih.gov/pubmed/20670044Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. - http://www.ncbi.nlm.nih.gov/pubmed/7818116Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. - http://www.ncbi.nlm.nih.gov/pubmed/8901078Oxycodone is found to suppress sodium currents in the thalamic regions of the brain at high doses and is an effect that is independent of the MOR/u-opioid recepter and therefore this mechanism is not blocked by the use of naloxone - http://www.sciencedirect.com/science/article/pii/S0304394009001268Oxycodone is found to have longer lasting more efficient effects on pain due to neuropathy because of having GABA-B agonist properties -http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0091297Oxycodone when paired with an ultra low dose of naltrexone, an opioid antagonist, oxycodone has a longer duration of pain relief - http://www.sciencedirect.com/science/article/pii/S1526590005004128Oxycodone has been found to be an effective treatment for restless leg syndrome - http://europepmc.org/abstract/med/8341893Pharmacokinetics of oxycodone done orally and intramuscularly http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.1992.tb04090.x/abstract